nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—HTR7—enteric nervous system—pancreatic cancer	0.0431	0.518	CbGeAlD
Lurasidone—HTR2A—enteric nervous system—pancreatic cancer	0.0269	0.323	CbGeAlD
Lurasidone—ADRA2A—islet of Langerhans—pancreatic cancer	0.00302	0.0363	CbGeAlD
Lurasidone—ADRA2C—pancreas—pancreatic cancer	0.00266	0.032	CbGeAlD
Lurasidone—HTR7—digestive system—pancreatic cancer	0.00247	0.0297	CbGeAlD
Lurasidone—ADRA2A—pancreas—pancreatic cancer	0.00212	0.0255	CbGeAlD
Lurasidone—HTR2A—digestive system—pancreatic cancer	0.00154	0.0185	CbGeAlD
Lurasidone—CYP3A4—digestive system—pancreatic cancer	0.00143	0.0172	CbGeAlD
Lurasidone—Insomnia—Irinotecan—pancreatic cancer	0.000805	0.00126	CcSEcCtD
Lurasidone—Cardiac disorder—Docetaxel—pancreatic cancer	0.000804	0.00126	CcSEcCtD
Lurasidone—Vomiting—Tamoxifen—pancreatic cancer	0.000803	0.00125	CcSEcCtD
Lurasidone—Lethargy—Doxorubicin—pancreatic cancer	0.000798	0.00125	CcSEcCtD
Lurasidone—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000798	0.00125	CcSEcCtD
Lurasidone—Hypotension—Fluorouracil—pancreatic cancer	0.000797	0.00124	CcSEcCtD
Lurasidone—Rash—Tamoxifen—pancreatic cancer	0.000796	0.00124	CcSEcCtD
Lurasidone—Dermatitis—Tamoxifen—pancreatic cancer	0.000795	0.00124	CcSEcCtD
Lurasidone—Vomiting—Erlotinib—pancreatic cancer	0.000794	0.00124	CcSEcCtD
Lurasidone—Dyspnoea—Irinotecan—pancreatic cancer	0.000794	0.00124	CcSEcCtD
Lurasidone—Somnolence—Irinotecan—pancreatic cancer	0.000792	0.00124	CcSEcCtD
Lurasidone—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000791	0.00124	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00079	0.00123	CcSEcCtD
Lurasidone—Rash—Erlotinib—pancreatic cancer	0.000787	0.00123	CcSEcCtD
Lurasidone—Dermatitis—Erlotinib—pancreatic cancer	0.000787	0.00123	CcSEcCtD
Lurasidone—Angiopathy—Docetaxel—pancreatic cancer	0.000786	0.00123	CcSEcCtD
Lurasidone—Insomnia—Gemcitabine—pancreatic cancer	0.000785	0.00122	CcSEcCtD
Lurasidone—Dyspepsia—Irinotecan—pancreatic cancer	0.000784	0.00122	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000782	0.00122	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000777	0.00121	CcSEcCtD
Lurasidone—Asthenia—Sunitinib—pancreatic cancer	0.000776	0.00121	CcSEcCtD
Lurasidone—Decreased appetite—Irinotecan—pancreatic cancer	0.000774	0.00121	CcSEcCtD
Lurasidone—Arrhythmia—Docetaxel—pancreatic cancer	0.000774	0.00121	CcSEcCtD
Lurasidone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000773	0.00121	CcSEcCtD
Lurasidone—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000772	0.0012	CcSEcCtD
Lurasidone—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000772	0.0012	CcSEcCtD
Lurasidone—Insomnia—Fluorouracil—pancreatic cancer	0.000771	0.0012	CcSEcCtD
Lurasidone—Somnolence—Gemcitabine—pancreatic cancer	0.000771	0.0012	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000769	0.0012	CcSEcCtD
Lurasidone—Fatigue—Irinotecan—pancreatic cancer	0.000768	0.0012	CcSEcCtD
Lurasidone—Pruritus—Sunitinib—pancreatic cancer	0.000765	0.00119	CcSEcCtD
Lurasidone—Breast disorder—Epirubicin—pancreatic cancer	0.000763	0.00119	CcSEcCtD
Lurasidone—Dyspnoea—Fluorouracil—pancreatic cancer	0.00076	0.00119	CcSEcCtD
Lurasidone—Mental disorder—Docetaxel—pancreatic cancer	0.000759	0.00119	CcSEcCtD
Lurasidone—Somnolence—Fluorouracil—pancreatic cancer	0.000758	0.00118	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000755	0.00118	CcSEcCtD
Lurasidone—Malnutrition—Docetaxel—pancreatic cancer	0.000754	0.00118	CcSEcCtD
Lurasidone—Decreased appetite—Gemcitabine—pancreatic cancer	0.000754	0.00118	CcSEcCtD
Lurasidone—Dyspepsia—Fluorouracil—pancreatic cancer	0.000751	0.00117	CcSEcCtD
Lurasidone—Nausea—Tamoxifen—pancreatic cancer	0.00075	0.00117	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000749	0.00117	CcSEcCtD
Lurasidone—Fatigue—Gemcitabine—pancreatic cancer	0.000748	0.00117	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—pancreatic cancer	0.000748	0.00117	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000745	0.00116	CcSEcCtD
Lurasidone—Nausea—Erlotinib—pancreatic cancer	0.000742	0.00116	CcSEcCtD
Lurasidone—Decreased appetite—Fluorouracil—pancreatic cancer	0.000741	0.00116	CcSEcCtD
Lurasidone—Diarrhoea—Sunitinib—pancreatic cancer	0.00074	0.00115	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000736	0.00115	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000732	0.00114	CcSEcCtD
Lurasidone—Influenza—Epirubicin—pancreatic cancer	0.00073	0.00114	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—pancreatic cancer	0.00073	0.00114	CcSEcCtD
Lurasidone—Back pain—Docetaxel—pancreatic cancer	0.00073	0.00114	CcSEcCtD
Lurasidone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000728	0.00114	CcSEcCtD
Lurasidone—Muscle spasms—Docetaxel—pancreatic cancer	0.000725	0.00113	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—pancreatic cancer	0.000723	0.00113	CcSEcCtD
Lurasidone—Dizziness—Sunitinib—pancreatic cancer	0.000715	0.00112	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000714	0.00111	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000714	0.00111	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—pancreatic cancer	0.000711	0.00111	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—pancreatic cancer	0.000706	0.0011	CcSEcCtD
Lurasidone—Abdominal pain—Irinotecan—pancreatic cancer	0.000704	0.0011	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000699	0.00109	CcSEcCtD
Lurasidone—Anaemia—Docetaxel—pancreatic cancer	0.000697	0.00109	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—pancreatic cancer	0.000692	0.00108	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000689	0.00108	CcSEcCtD
Lurasidone—Vomiting—Sunitinib—pancreatic cancer	0.000687	0.00107	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—pancreatic cancer	0.000683	0.00107	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—pancreatic cancer	0.000683	0.00107	CcSEcCtD
Lurasidone—Rash—Sunitinib—pancreatic cancer	0.000682	0.00106	CcSEcCtD
Lurasidone—Dermatitis—Sunitinib—pancreatic cancer	0.000681	0.00106	CcSEcCtD
Lurasidone—Syncope—Docetaxel—pancreatic cancer	0.000676	0.00106	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—pancreatic cancer	0.000676	0.00105	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—pancreatic cancer	0.000676	0.00105	CcSEcCtD
Lurasidone—Leukopenia—Docetaxel—pancreatic cancer	0.000675	0.00105	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—pancreatic cancer	0.000669	0.00104	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—pancreatic cancer	0.000664	0.00104	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000663	0.00104	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000659	0.00103	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—pancreatic cancer	0.000658	0.00103	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—pancreatic cancer	0.000654	0.00102	CcSEcCtD
Lurasidone—Hypertension—Docetaxel—pancreatic cancer	0.000651	0.00102	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—pancreatic cancer	0.000651	0.00102	CcSEcCtD
Lurasidone—Infestation—Epirubicin—pancreatic cancer	0.000651	0.00102	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—pancreatic cancer	0.000642	0.001	CcSEcCtD
Lurasidone—Nausea—Sunitinib—pancreatic cancer	0.000642	0.001	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—pancreatic cancer	0.00064	0.000999	CcSEcCtD
Lurasidone—Asthenia—Irinotecan—pancreatic cancer	0.000639	0.000998	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000638	0.000996	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—pancreatic cancer	0.000633	0.000988	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—pancreatic cancer	0.000632	0.000986	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—pancreatic cancer	0.000632	0.000986	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—pancreatic cancer	0.000628	0.000981	CcSEcCtD
Lurasidone—Asthenia—Gemcitabine—pancreatic cancer	0.000622	0.000972	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000616	0.000961	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—pancreatic cancer	0.000615	0.00096	CcSEcCtD
Lurasidone—Pruritus—Gemcitabine—pancreatic cancer	0.000614	0.000958	CcSEcCtD
Lurasidone—Infection—Docetaxel—pancreatic cancer	0.000612	0.000955	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000609	0.000952	CcSEcCtD
Lurasidone—Diarrhoea—Irinotecan—pancreatic cancer	0.000609	0.000951	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—pancreatic cancer	0.000608	0.000949	CcSEcCtD
Lurasidone—Shock—Docetaxel—pancreatic cancer	0.000606	0.000946	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—pancreatic cancer	0.000604	0.000943	CcSEcCtD
Lurasidone—Pruritus—Fluorouracil—pancreatic cancer	0.000603	0.000942	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—pancreatic cancer	0.000602	0.00094	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—pancreatic cancer	0.000602	0.00094	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—pancreatic cancer	0.000601	0.000938	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—pancreatic cancer	0.000598	0.000934	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—pancreatic cancer	0.000595	0.000929	CcSEcCtD
Lurasidone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000594	0.000927	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—pancreatic cancer	0.000592	0.000925	CcSEcCtD
Lurasidone—Dizziness—Irinotecan—pancreatic cancer	0.000589	0.000919	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000586	0.000914	CcSEcCtD
Lurasidone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000584	0.000911	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000577	0.000901	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—pancreatic cancer	0.000575	0.000898	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000574	0.000897	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—pancreatic cancer	0.000573	0.000894	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00057	0.000889	CcSEcCtD
Lurasidone—Vomiting—Irinotecan—pancreatic cancer	0.000566	0.000884	CcSEcCtD
Lurasidone—Dizziness—Fluorouracil—pancreatic cancer	0.000564	0.000881	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000562	0.000878	CcSEcCtD
Lurasidone—Rash—Irinotecan—pancreatic cancer	0.000561	0.000877	CcSEcCtD
Lurasidone—Dermatitis—Irinotecan—pancreatic cancer	0.000561	0.000876	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000561	0.000876	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—pancreatic cancer	0.000557	0.000869	CcSEcCtD
Lurasidone—Vomiting—Gemcitabine—pancreatic cancer	0.000552	0.000861	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—pancreatic cancer	0.000551	0.00086	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—pancreatic cancer	0.000549	0.000857	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—pancreatic cancer	0.000547	0.000854	CcSEcCtD
Lurasidone—Rash—Gemcitabine—pancreatic cancer	0.000547	0.000854	CcSEcCtD
Lurasidone—Dermatitis—Gemcitabine—pancreatic cancer	0.000546	0.000853	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—pancreatic cancer	0.000546	0.000853	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—pancreatic cancer	0.000542	0.000847	CcSEcCtD
Lurasidone—Vomiting—Fluorouracil—pancreatic cancer	0.000542	0.000847	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—pancreatic cancer	0.000542	0.000846	CcSEcCtD
Lurasidone—Rash—Fluorouracil—pancreatic cancer	0.000538	0.00084	CcSEcCtD
Lurasidone—Dermatitis—Fluorouracil—pancreatic cancer	0.000537	0.000839	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—pancreatic cancer	0.000535	0.000835	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000534	0.000834	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000531	0.00083	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000531	0.00083	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—pancreatic cancer	0.000531	0.000829	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—pancreatic cancer	0.00053	0.000828	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—pancreatic cancer	0.00053	0.000828	CcSEcCtD
Lurasidone—Nausea—Irinotecan—pancreatic cancer	0.000529	0.000826	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—pancreatic cancer	0.000522	0.000815	CcSEcCtD
Lurasidone—Nausea—Gemcitabine—pancreatic cancer	0.000515	0.000804	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—pancreatic cancer	0.000512	0.000799	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—pancreatic cancer	0.000509	0.000794	CcSEcCtD
Lurasidone—Nausea—Fluorouracil—pancreatic cancer	0.000507	0.000791	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—pancreatic cancer	0.000505	0.000789	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000503	0.000786	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000502	0.000784	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—pancreatic cancer	0.000501	0.000783	CcSEcCtD
Lurasidone—Back pain—Epirubicin—pancreatic cancer	0.000492	0.000768	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—pancreatic cancer	0.000491	0.000766	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—pancreatic cancer	0.000489	0.000764	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—pancreatic cancer	0.000487	0.00076	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—pancreatic cancer	0.000483	0.000754	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—pancreatic cancer	0.000479	0.000749	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—pancreatic cancer	0.000474	0.00074	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—pancreatic cancer	0.000471	0.000735	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—pancreatic cancer	0.00047	0.000734	CcSEcCtD
Lurasidone—Agitation—Epirubicin—pancreatic cancer	0.000468	0.00073	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—pancreatic cancer	0.000464	0.000724	CcSEcCtD
Lurasidone—Malaise—Epirubicin—pancreatic cancer	0.000459	0.000716	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—pancreatic cancer	0.000457	0.000714	CcSEcCtD
Lurasidone—Syncope—Epirubicin—pancreatic cancer	0.000456	0.000712	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—pancreatic cancer	0.000455	0.000711	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—pancreatic cancer	0.000455	0.000711	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000453	0.000707	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000447	0.000698	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—pancreatic cancer	0.000444	0.000693	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—pancreatic cancer	0.000442	0.00069	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—pancreatic cancer	0.000441	0.000688	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—pancreatic cancer	0.000439	0.000686	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—pancreatic cancer	0.000436	0.00068	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—pancreatic cancer	0.000435	0.000679	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—pancreatic cancer	0.000433	0.000676	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—pancreatic cancer	0.000433	0.000675	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—pancreatic cancer	0.000432	0.000674	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.00043	0.000672	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—pancreatic cancer	0.000425	0.000663	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—pancreatic cancer	0.000424	0.000661	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—pancreatic cancer	0.000423	0.00066	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—pancreatic cancer	0.000422	0.000659	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—pancreatic cancer	0.000421	0.000658	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—pancreatic cancer	0.000421	0.000658	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000414	0.000646	CcSEcCtD
Lurasidone—Infection—Epirubicin—pancreatic cancer	0.000413	0.000644	CcSEcCtD
Lurasidone—Shock—Epirubicin—pancreatic cancer	0.000409	0.000638	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—pancreatic cancer	0.000408	0.000637	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—pancreatic cancer	0.000407	0.000636	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—pancreatic cancer	0.000407	0.000636	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—pancreatic cancer	0.000406	0.000635	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—pancreatic cancer	0.000405	0.000633	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—pancreatic cancer	0.000403	0.00063	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000401	0.000627	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—pancreatic cancer	0.000401	0.000626	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—pancreatic cancer	0.000399	0.000624	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000398	0.000621	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—pancreatic cancer	0.000392	0.000612	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—pancreatic cancer	0.000391	0.000611	CcSEcCtD
Lurasidone—Rash—Docetaxel—pancreatic cancer	0.000388	0.000606	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—pancreatic cancer	0.000388	0.000606	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—pancreatic cancer	0.000388	0.000605	CcSEcCtD
Lurasidone—Infection—Doxorubicin—pancreatic cancer	0.000382	0.000596	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000378	0.000591	CcSEcCtD
Lurasidone—Shock—Doxorubicin—pancreatic cancer	0.000378	0.00059	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000377	0.000588	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—pancreatic cancer	0.000376	0.000586	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—pancreatic cancer	0.000375	0.000585	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—pancreatic cancer	0.000373	0.000583	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000371	0.00058	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—pancreatic cancer	0.00037	0.000578	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—pancreatic cancer	0.000369	0.000576	CcSEcCtD
Lurasidone—Nausea—Docetaxel—pancreatic cancer	0.000366	0.000571	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—pancreatic cancer	0.000365	0.000571	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—pancreatic cancer	0.000361	0.000564	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—pancreatic cancer	0.000359	0.00056	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000358	0.00056	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—pancreatic cancer	0.000358	0.000559	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00035	0.000546	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—pancreatic cancer	0.000347	0.000543	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—pancreatic cancer	0.000343	0.000535	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—pancreatic cancer	0.000342	0.000533	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00034	0.00053	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—pancreatic cancer	0.000338	0.000528	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000334	0.000521	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000332	0.000518	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—pancreatic cancer	0.000331	0.000517	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—pancreatic cancer	0.000328	0.000512	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000314	0.00049	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000304	0.000474	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—pancreatic cancer	0.000298	0.000465	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—pancreatic cancer	0.000294	0.000459	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—pancreatic cancer	0.000284	0.000444	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—pancreatic cancer	0.000276	0.00043	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—pancreatic cancer	0.000275	0.000429	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—pancreatic cancer	0.000272	0.000424	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—pancreatic cancer	0.000264	0.000412	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—pancreatic cancer	0.000263	0.00041	CcSEcCtD
Lurasidone—Rash—Epirubicin—pancreatic cancer	0.000262	0.000409	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—pancreatic cancer	0.000262	0.000408	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—pancreatic cancer	0.000254	0.000397	CcSEcCtD
Lurasidone—Nausea—Epirubicin—pancreatic cancer	0.000247	0.000385	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—pancreatic cancer	0.000244	0.000381	CcSEcCtD
Lurasidone—Rash—Doxorubicin—pancreatic cancer	0.000242	0.000378	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—pancreatic cancer	0.000242	0.000378	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—pancreatic cancer	0.000228	0.000356	CcSEcCtD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.82e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CB—pancreatic cancer	4.81e-05	0.000174	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PPARG—pancreatic cancer	4.8e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APOE—pancreatic cancer	4.76e-05	0.000172	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HIF1A—pancreatic cancer	4.72e-05	0.000171	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TSC2—pancreatic cancer	4.71e-05	0.00017	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCL8—pancreatic cancer	4.7e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	4.68e-05	0.000169	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—AKT1—pancreatic cancer	4.68e-05	0.000169	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KDR—pancreatic cancer	4.66e-05	0.000169	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	4.65e-05	0.000168	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	4.63e-05	0.000168	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL8—pancreatic cancer	4.63e-05	0.000167	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APOE—pancreatic cancer	4.61e-05	0.000167	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—PIK3CA—pancreatic cancer	4.58e-05	0.000166	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	4.57e-05	0.000165	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KDR—pancreatic cancer	4.51e-05	0.000163	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—TP53—pancreatic cancer	4.5e-05	0.000163	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TERT—pancreatic cancer	4.48e-05	0.000162	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APOE—pancreatic cancer	4.47e-05	0.000162	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CB—pancreatic cancer	4.44e-05	0.000161	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NFKBIA—pancreatic cancer	4.44e-05	0.00016	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TERT—pancreatic cancer	4.4e-05	0.000159	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOTCH1—pancreatic cancer	4.39e-05	0.000159	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	4.38e-05	0.000158	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CD—pancreatic cancer	4.37e-05	0.000158	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HRAS—pancreatic cancer	4.3e-05	0.000156	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CG—pancreatic cancer	4.3e-05	0.000155	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—NRAS—pancreatic cancer	4.3e-05	0.000155	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NFKBIA—pancreatic cancer	4.29e-05	0.000155	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HIF1A—pancreatic cancer	4.28e-05	0.000155	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TSC2—pancreatic cancer	4.27e-05	0.000155	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL8—pancreatic cancer	4.27e-05	0.000154	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOTCH1—pancreatic cancer	4.25e-05	0.000154	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGF—pancreatic cancer	4.25e-05	0.000154	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HRAS—pancreatic cancer	4.24e-05	0.000153	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HIF1A—pancreatic cancer	4.21e-05	0.000152	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	4.21e-05	0.000152	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TSC2—pancreatic cancer	4.2e-05	0.000152	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.18e-05	0.000151	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOE—pancreatic cancer	4.18e-05	0.000151	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CG—pancreatic cancer	4.16e-05	0.00015	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—NRAS—pancreatic cancer	4.16e-05	0.00015	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—pancreatic cancer	4.12e-05	0.000149	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—DPYD—pancreatic cancer	4.11e-05	0.000149	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOE—pancreatic cancer	4.11e-05	0.000149	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGF—pancreatic cancer	4.11e-05	0.000149	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KDR—pancreatic cancer	4.09e-05	0.000148	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CASP3—pancreatic cancer	4.09e-05	0.000148	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	4.04e-05	0.000146	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KDR—pancreatic cancer	4.03e-05	0.000146	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	4.01e-05	0.000145	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCND1—pancreatic cancer	3.98e-05	0.000144	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CTNNB1—pancreatic cancer	3.94e-05	0.000142	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—EGFR—pancreatic cancer	3.91e-05	0.000142	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	3.9e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—pancreatic cancer	3.9e-05	0.000141	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	3.89e-05	0.000141	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—pancreatic cancer	3.86e-05	0.00014	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	3.86e-05	0.00014	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PTEN—pancreatic cancer	3.84e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	3.83e-05	0.000139	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NFKBIA—pancreatic cancer	3.83e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	3.82e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	3.81e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—pancreatic cancer	3.8e-05	0.000138	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	3.79e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	3.79e-05	0.000137	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	3.78e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—pancreatic cancer	3.77e-05	0.000137	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	3.77e-05	0.000136	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	3.77e-05	0.000136	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—pancreatic cancer	3.74e-05	0.000135	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	3.74e-05	0.000135	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.74e-05	0.000135	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGF—pancreatic cancer	3.73e-05	0.000135	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.71e-05	0.000134	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	3.71e-05	0.000134	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	3.7e-05	0.000134	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGF—pancreatic cancer	3.67e-05	0.000133	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	3.66e-05	0.000133	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	3.65e-05	0.000132	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.62e-05	0.000131	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	3.58e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SRC—pancreatic cancer	3.56e-05	0.000129	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	3.55e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	3.49e-05	0.000126	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—pancreatic cancer	3.47e-05	0.000125	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	3.45e-05	0.000125	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	3.44e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—pancreatic cancer	3.43e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRAS—pancreatic cancer	3.42e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.4e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	3.38e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.38e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	3.38e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	3.34e-05	0.000121	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	3.32e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	3.29e-05	0.000119	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—pancreatic cancer	3.29e-05	0.000119	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	3.29e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.28e-05	0.000119	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	3.26e-05	0.000118	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	3.25e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.23e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	3.19e-05	0.000116	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—pancreatic cancer	3.19e-05	0.000115	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	3.18e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—pancreatic cancer	3.18e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	3.16e-05	0.000114	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	3.14e-05	0.000114	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—pancreatic cancer	3.12e-05	0.000113	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	3.09e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	3.08e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—pancreatic cancer	3.07e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	3.06e-05	0.000111	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	3.06e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	3.04e-05	0.00011	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	3.03e-05	0.00011	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CD44—pancreatic cancer	3.02e-05	0.000109	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.98e-05	0.000108	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	2.97e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.96e-05	0.000107	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—pancreatic cancer	2.95e-05	0.000107	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	2.95e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.94e-05	0.000106	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.93e-05	0.000106	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	2.93e-05	0.000106	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.92e-05	0.000106	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	2.91e-05	0.000105	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GCG—pancreatic cancer	2.9e-05	0.000105	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.89e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	2.86e-05	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	2.85e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	2.84e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.84e-05	0.000103	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.82e-05	0.000102	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.78e-05	0.0001	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	2.77e-05	0.0001	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	2.77e-05	0.0001	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.76e-05	9.98e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	2.75e-05	9.96e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	2.73e-05	9.89e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—STK11—pancreatic cancer	2.72e-05	9.86e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	2.71e-05	9.82e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	2.71e-05	9.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	2.68e-05	9.72e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.68e-05	9.71e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—pancreatic cancer	2.67e-05	9.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.67e-05	9.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.66e-05	9.62e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.64e-05	9.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	2.64e-05	9.54e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—pancreatic cancer	2.62e-05	9.48e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.62e-05	9.46e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.59e-05	9.36e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.59e-05	9.36e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	2.57e-05	9.3e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.56e-05	9.27e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	2.55e-05	9.24e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.55e-05	9.21e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	2.54e-05	9.2e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	2.54e-05	9.18e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.52e-05	9.12e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.51e-05	9.09e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—pancreatic cancer	2.51e-05	9.06e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.5e-05	9.04e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	2.49e-05	9e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	2.49e-05	8.99e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	2.47e-05	8.94e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	2.47e-05	8.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	2.46e-05	8.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	2.46e-05	8.89e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	2.46e-05	8.88e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.44e-05	8.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.4e-05	8.69e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	2.4e-05	8.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	2.38e-05	8.61e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	2.36e-05	8.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	2.36e-05	8.53e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.34e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	2.32e-05	8.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	2.32e-05	8.38e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.32e-05	8.38e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	2.31e-05	8.37e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.29e-05	8.3e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	2.29e-05	8.28e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	2.28e-05	8.26e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	2.28e-05	8.25e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.26e-05	8.16e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.25e-05	8.14e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	2.24e-05	8.09e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.24e-05	8.09e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.23e-05	8.08e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.23e-05	8.06e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	2.22e-05	8.03e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—pancreatic cancer	2.21e-05	8e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	2.2e-05	7.95e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	2.19e-05	7.93e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	2.18e-05	7.9e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.18e-05	7.89e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	2.11e-05	7.65e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—pancreatic cancer	2.08e-05	7.51e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	2.07e-05	7.5e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	2.07e-05	7.49e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	2.04e-05	7.39e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	2.04e-05	7.37e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—pancreatic cancer	2.03e-05	7.34e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	2.02e-05	7.31e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.01e-05	7.26e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	2e-05	7.23e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	2e-05	7.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.99e-05	7.22e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.94e-05	7.03e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.94e-05	7.02e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.92e-05	6.94e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOE—pancreatic cancer	1.91e-05	6.9e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.9e-05	6.86e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.89e-05	6.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.89e-05	6.82e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.88e-05	6.8e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.86e-05	6.72e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.86e-05	6.72e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.85e-05	6.71e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.82e-05	6.57e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	1.8e-05	6.5e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.76e-05	6.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.73e-05	6.27e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.72e-05	6.22e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.72e-05	6.21e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.7e-05	6.17e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.68e-05	6.07e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.66e-05	6.01e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.64e-05	5.93e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.63e-05	5.9e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.6e-05	5.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.59e-05	5.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.58e-05	5.71e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.54e-05	5.57e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.53e-05	5.52e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.51e-05	5.47e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.46e-05	5.28e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.44e-05	5.21e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.42e-05	5.12e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.32e-05	4.77e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.31e-05	4.73e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.29e-05	4.66e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.14e-05	4.12e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	8.03e-06	2.91e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—pancreatic cancer	6.56e-06	2.38e-05	CbGpPWpGaD
